Myopathy, Myofibrillar, Desmin-Related Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Myopathy, Myofibrillar, Desmin-Related Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Myopathy, Myofibrillar, Desmin-Related; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Myopathy, Myofibrillar, Desmin-Related receives an overall strategic score of 72/100. The opportunity combines an unmet-need score of 85/100, competition score of 43/100 and market-attractiveness score of 68/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

A rare genetic skeletal muscle disease with characteristics of abnormal chimeric aggregates of desmin and other cytoskeletal proteins and granulofilamentous material at the ultrastructural level in muscle biopsies and variable clinical/ myopathological features, age of disease onset and rate of disease progression. Patients present with bilateral skeletal muscle weakness that starts in distal leg muscles and spreads proximally, sometimes involving trunk, neck flexors and facial muscles and often cardiomyopathy manifested by conduction blocks, arrhythmias, chronic heart failure, and sometimes tachyarrhythmia. Weakness eventually leads to wheelchair dependence. Respiratory insufficiency can be a major cause of disability and death, beginning with nocturnal hyperventilation with oxygen desaturation and progressing to daytime respiratory failure. Caused by heterozygous, homozygous, or compound heterozygous mutation in the desmin gene (DES) on chromosome 2q35.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Myopathy, Myofibrillar, Desmin-Related, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID af9800410b2848bbb6d96d65119b413f and MeSH identifier C563319. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: The epidemiology of myasthenia gravis

The epidemiology of myasthenia gravis JML | REVIEW The epidemiology of myasthenia gravis Ana-Maria Bubuioc 1 , Aigerim Kudebayeva 2 , Saule Turuspekova 3 , Vitalie Lisnic 1 * , Maurizio Angelo Leone 4 Author Affiliations: * Corresponding Author: Corresponding Author: Vitalie Lisnic, MD, PhD, Professor, Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy, 2 Korolenko str., MD – 2028, Chisinau, the Republic of Moldova. Fax: +373-022737200 Phone: +373-79456641 E-mail: vitalie.lisnic@usmf.md fi 1. Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy Chisinau, the Republic of Moldova 2. Department of Neurology, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan 3. Department of Nervous Diseases with course of Neurosurgery, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan 4. Neurology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy ABSTRACT DOI 10.25122/jml-2020-0145 Dates Received: 31 August 2020 Accepted: 14 October 2020

Review the underlying epidemiology source

Evidence signal 2: Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data Epidemiology of myasthenia gravis in France:Incidence, prevalence, and comorbidities based onnational healthcare insurance claims data

groups showed that the incidence rate was 11.5 per million person-years for EOMG and 118.5 per million person-years for LOMG (P < 0.001). During the same period, the prevalence of MG ranged between 331 [282–386] cases per million people in 2008 and 586 [527–649] cases per million people in 2016 (Fig. 3). Over the last five years of the study period, the prevalence was above 500 per million people. 3.2. Comorbidities After the exclusion of 35 patients recruited through criterion number 5, 296 patients were included in the analyses. Thymoma and thymectomy were more frequent among MG patients than matched controls, with a very high SRR: 682 (95% CI [288–1319]) and 389 (95% CI [160–752]), respectively (Table 1). Autoimmune thyroid disorders were also more frequent among MG patients than matched controls (SRR of 2.27, 95% CI [1.32–4.18]), as well as rheumatoid arthritis (SRR of 6.77, 95% CI [1.28–18.3]). The number of cases of other autoimmune diseases, such as systemic lupus erythematosus, Biermer’s disease, and polymyositis, were too limited among MG patients to allow statistical testing. Approximately 22% of MG patients were treated for cancer during the study period versus only 5.2% in the EGB population, with a SRR of 2.38 (95% CI [1.64–3.46]). MG: myasthenia gravis; EGB: E´chantillon ge´ne´raliste des be´ne´ficiaires. Data of the EGB population were extracted in 2017. Data of MG patients were extracted at the time of the last observation (death or last information). The comorbidity ‘‘cancer’’ was retained for patients who were treated for cancer and not for those for whom th

Review the underlying epidemiology source

Evidence signal 3: Prevalence of vasculitis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies and spondyloarthritis in Australia : a systematic review and meta‐analysis Prevalence of vasculitis, systemic lupus erythematosus,rheumatoid arthritis, systemic sclerosis, idiopathic inflammatorymyopathies and spondyloarthritis in Australia: a systematicreview and meta-analysis

Idiopathic inflammatory myopathies The six studies of IIM used different disease definitions (Section S6.1). Synthesising the results of studies that use different definitions is challenging.68,69 We approached this by disaggregating into IIM, dermatomy- ositis (DM), polymyositis (PM) and inclusion body myo- sitis (IBM). Meta-analysis The overall incidence of IIM was 9.96 (5.78–17.16) per million person-years, based on three studies reporting rates of 7.4–19 per million person-years,12,70,71 identify- ing cases from biopsy data alone,12 biopsy plus hospital data70 or ICD codes alone.71 As ICD codes may over- estimate IIM,68 we assessed the impact of this study: excluding it reduced the overall incidence to 7.7 (7.1– 8.3) per million person-years (Section S6.3). The forest plot and individual incidence of PM and DM are in the Supporting Information (Sections S6.4 and S6.5). The pooled prevalence of IBM was 27.73 (12.32–49.22) per million (Section S6.6), derived from three studies12,71,72 (the fourth was excluded due to population overlap73), identifying cases from biopsy data alone,12 biopsy data plus manual case finding from local clinicians72 or ICD codes alone.71 Although biopsy-based studies have limitations (dis- cussed later), the highest IBM prevalence was reported in a biopsy-only study,12 whose authors attributed this high prevlaence to increasing diagnostic awareness, compared to historical studies.12 In contrast, however, the most recent study71 relied solely on ICD codes and reported a lower prevalence, possibly due to under- ascertainment. The ICD-10-AM code used by

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Myopathy, Myofibrillar, Desmin-Related, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Myopathy, Myofibrillar, Desmin-Related should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: hERG

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Channel properties are modulated by cAMP and subunit assembly (PubMed:10837251). Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity (PubMed:10219239, PubMed:9230439). Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.

The proposed mechanism anchor for this landscape is KCNH2. Target selection does not imply that every Myopathy, Myofibrillar, Desmin-Related patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 2 matched registered studies overall. The most recent records sampled for this report are:

• NCT06661317 — Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.; status: Unknown status; phase: Not Applicable; sponsor(s): Warszawski Uniwersytet Medyczny; enrollment: 200.
• DRKS00028194 — Mitochondrial function in patients with desminopathy; status: Complete; phase: Not Applicable; sponsor(s): not stated; enrollment: 20.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Myopathy, Myofibrillar, Desmin-Related program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Myopathy, Myofibrillar, Desmin-Related. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Myopathy, Myofibrillar, Desmin-Related.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Myopathy, Myofibrillar, Desmin-Related, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that KCNH2 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Myopathy, Myofibrillar, Desmin-Related merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where KCNH2 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Myopathy, Myofibrillar, Desmin-Related offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.